Search tips
Search criteria 


Logo of molvisLink to Publisher's site
Mol Vis. 2010; 16: 1848–1853.
Published online 2010 September 12.
PMCID: PMC2956671

Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells



Vascular endothelial growth factor (VEGF) is well known for its role in pathologic neovascularization, including wet age-related macular degeneration. However, a growing body of evidence indicates that VEGF is also neuroprotective of non-vascular cells in various animal models through reduction of oxidative stress. In light of the widespread use of intraocular anti-VEGF therapies for age-related macular degeneration (AMD), we evaluated the impact of anti-VEGF agents on the neuroprotective effect of VEGF on retinal ganglion cells.


Staurosporine differentiated retinal ganglion cells were treated with increasing doses of VEGF in the presence of hydrogen peroxide. After optimization, an increasing concentration of bevacizumab was added to neutralize VEGF-mediated protection. The degree of oxidative damage was measured at various time points using buthionine sulfoxime (BSO), a glutathione reductase inhibitor. Cell viability was assessed using WST-1 and Crystal violet assays.


VEGF (200 ng/ml) protected differentiated retinal ganglion cells (RGC)-5 against H202-mediated oxidative stress. This effect was eliminated by co-treatment with bevacizumab (2.0 mg/ml), which by itself was not cytotoxic.


These results indicate an important role for VEGF in the maintenance of retinal ganglion cells.


Vascular endothelial growth factor (VEGF), a secreted 46 kDa glycoprotein, is an endothelial cell-specific angiogenic as well as a vasopermeable factor [1,2]. Although initially thought to be endothelial-specific, VEGF plays a major role during the development and maturation of neural tissue, including the retina [3]. During development, VEGF is expressed by astrocytes in the retinal ganglion cell layer, by cells of inner nuclear layer, Müller cells, and retinal pigment epithelial cells [4,5]. In the adult retina, VEGF is expressed in the absence of active neovascularization and is implicated in the maintenance and function of adult retina neuronal cells [6]. VEGF-A, an isoform of VEGF, reduces apoptosis in retinal neurons after ischemic injury and delays degeneration of retinal ganglion cells after axotomy [7]. Upregulation of VEGF occurs in many ischemic conditions of the retina, including age-related macular degeneration (AMD) and diabetic retinopathy [8,9]. Higher intraocular VEGF levels lead to subretinal and vitreous hemorrhage, retinal detachment, and often blindness [10].

Intravitreal injections of anti-VEGF agents such as bevacizumab are widely used in the treatment of AMD to reduce the angiogenesis associated with choroidal neovascularization [11,12]. Hypothetically, repeated treatment with anti-VEGF agents should interfere with the neuroprotective action of VEGF. Recently, Saint-Geniez et al. [6] have shown in animal studies that small, interfering RNA (siRNA)-mediated gene silencing of VEGF led to a reduction in the thickness of retinal cell layers. They concluded that VEGF has a neuroprotective role in the survival of retinal neurons. In this study, we tested this hypothesis in a cell culture model by investigating the neuroprotective effect of VEGF on differentiated rat retinal ganglion cell, RGC-5 after oxidative stress, and whether treatment with bevacizumab can abrogate this effect. We used the oxidative stress model to replicate the in vivo conditions, which are implicated in the pathogenesis of macular degeneration. Further, we found that retinal ischemic and oxidative injury leads to increased levels of VEGF, resulting in angiogenesis.


Cell culture

Rat retinal ganglion cells (RGC-5; Molecular Brain Research 86 [2001]) [112] were supplied courtesy of Dr. Neeraj Agarwal (UNT Health Science Center, Fort Worth, TX) and were cultured in Dubelco’s Modified Eagle Medium (DMEM: Invitrogen, Carlsbad, CA), containing 10% fetal bovine serum (FBS) and 100 U/ml penicillin/100 μg/ml streptomycin. All cells were maintained in logarithmic growth in T-75 flaskware and incubated at 37 °C in a 95% air and 5% CO2 environment.


RGC-5 cells were differentiated by treating the cells with Staurosporine using a technique previously described [13]. Morphologic evidence of a neuron cell line was determined using phase contrast bright-field microscopy. Further, immunocytochemistry was performed using a monoclonal antibody against class III β-tubulin to confirm differential expression of markers of neuronal differentiation.

Oxidative stress

Different concentrations of hydrogen peroxide (H2O2) were generated using serial dilution and applied to the Staurosporine-differentiated RGCs for 24 h to generate a dose response curve. Cell numbers were assessed using a Water Soluble Tetrazolium (WST)-1 (Roche, Mannheim, Germany) assay. Briefly, WST-1 is a tetrazolium salt that is cleaved by mitochondrial dehydrogenases in viable cells, producing a proportionate color change. Plates were then read on a spectrophotometer at 440 nm with reference wavelength at 690 nm.

Subsequently, differentiated cells were treated with increasing concentrations of human VEGF (hVEGF165; Invitrogen) in adjacent wells with alternate wells containing 800 µM H2O2 for 24 h. The difference in cell number between H2O2-treated and untreated wells were compared, using the WST-1 assay as described above. The aforementioned experiment was repeated in the presence of 25 μM buthionine sulfoxime (BSO), an inhibitor of glutathione (GSH) synthesis, thereby enhancing oxidative stress in our model. Cells were exposed to 25 μM BSO for 24 h following attachment and differentiation. Increasing concentrations of hVEGF165 were applied, followed by 24 h exposure to 800 μM H2O2.

To evaluate the effect of bevacizumab blockade of hVEGF165, we first conducted cytotoxicity experiments to explore any potential effect in our differentiated model. Cells were plated in 96-well plates at 2,000 cells/well, allowed to attach for 24 h, and subsequently differentiated with Staurosporine. Serial dilutions of commercially available bevacizumab (Avastin®: Genentech, San Francisco, CA) were performed to obtain treatment concentrations of 0.1, 1.0, and 2.0 mg/ml, and were applied for 24 h. H2O2 (1 mM) served as a positive control. Cell numbers were assessed using WST-1. Parallel experiments were conducted in a similar fashion and evaluated with crystal violet staining (CV). In brief, cells were fixed for 10 min in 4% formaldehyde, rinsed twice with PBS and dried. Cells were stained with 0.1% crystal violet solution for 30 min. Excess stain was washed once with PBS and twice with distilled water. Plates were dried again and then bound. Stain was dissolved in 100 μl of 10% acetic acid solution per well. Plates were read in a plate-reader with a 560 nm filter.

In subsequent experiments, cells were plated in 96-well plates and differentiated as described above. Increasing concentrations of bevacizumab were added to wells containing 200 ng VEGF165 and wells containing VEGF and 800 µM H2O2. Cell numbers using the WST-1 assay were determined following 24 h exposure.



Representative bright-field microscopy images demonstrate morphologic changes between differentiated and undifferentiated RGC-5 cells (Figure 1A).

Figure 1
Morphological and immunohistochemical differentiation of retinal ganglion cell (RGC)-5 cells. A: Phase contrast biomicroscopy comparing undifferentiated with differentiated RGC-5 following exposure to Staurosporine. Note the elongated neuronal processes ...

Immunocytochemistry demonstrates strong staining for class III β-tubulin, which highlights the elongated neuronal processes (Figure 1B, Antibody control and Figure 1C).

Oxidative stress

Twenty-four h H2O2 dose response studies identified 800 μM as the ideal concentration, reliably producing a 40% reduction in cell numbers compared with control (Figure 2A). This dose was used in subsequent experiments to test VEGF protection. 200 ng/ml of VEGF165 afforded the greatest protection to oxidative stress induced by 24 h exposure to 800 μM H2O2. There was a reduction in percentage decrease of cell numbers when cells were co-treated with VEGF and H2O2, compared with controls administered in a dose-dependent manner with increasing doses of VEGF. The maximum protection was provided at the 200 nM dose (p=0.001; Figure 2B). BSO increased H2O2-mediated reduction in cell numbers by 22%. hVEGF165 at 200 ng/mL provided the greatest protection, increasing cell numbers by 8%, p<0.0005 (Figure 2C).

Figure 2
Effects of vascular endothelial growth factor (VEGF) in oxidative stress induced cytotoxicity in retinal ganglion cell (RGC)-5 cells. A: Hydrogen p 258 eroxide dose response curve, following 24 h exposure, revealed 30%–35% reduction in cell numbers ...

Bevacizumab was not cytotoxic at any of the doses tested (p-values 0.34–0.69). This result was reflected in both WST-1 and CV assays (Figure 3A,B, respectively). H2O2 served as a positive control and consistently reduced cell numbers by 50%, p<0.0005. hVEGF165 afforded a 12% increase in cell numbers compared with control cells exposed to 800 μM H2O2, p<0.005. This effect was completely blocked by bevacizumab at 2.0 mg/ml, returning cell numbers to near control levels (Figure 4).

Figure 3
Effect of bevacizumab, following 24 h exposure, did not reveal evidence of cytotoxicity at any of the doses tested. Hydrogen peroxide (1 mM) served as a positive control. Cell numbers were assessed using Water Soluble Tetrazolium (WST)-1 (A) and crystal ...
Figure 4
Effect of bevacizumab on retinal ganglion cell (RGC)-5 viability. Vascular endothelial growth factor (VEGF) protected against hydrogen peroxide-mediated oxidative stress compared with untreated controls, *p-value <0.005. This effect was eliminated ...


Anti-VEGF therapy plays a significant role in the management of retinal and retinal vascular disorders [912]. Target therapy, though aimed against the angiogenic effect of VEGF, can reduce the potential benefit of VEGF in neuroprotection from oxidative stress. In our experiments, we provide evidence to suggest that addition of the VEGF inhibitor bevacizumab, while not toxic to differentiated RGC-5 at clinically relevant doses, blocked the protective effect of VEGF in our in vitro model.

In the human eye, there is increasing evidence that pathogenic oxidative mechanisms contribute to the progression of pathological conditions such as age-related macular degeneration and glaucoma [1418]. Phagocytosis of outer segments by the retinal pigment epithelium results in the generation of reactive oxygen species such as superoxide anion, hydroxyl, and hydrogen peroxide [19]. In different cell types, including vascular smooth muscles, VEGF expression is triggered under the influence of oxidative stress. Castilla et al. have demonstrated an increased VEGF expression in aortic endothelial cells that were exposed to cytotoxic agents such as hydrogen peroxide, cytochalasin, and cyclosporine [20]. In this study, we used H2O2 to induce oxidative stress to replicate the in vivo conditions that are implicated in the pathogenesis of AMD.

The development of the transformed rat RGC-5 provided a constant supply of cells for laboratory investigation, although their lack of morphologic characteristics of neurons has raised debate [13]. A recent report describes the process of differentiation of this cell line with the receptor tyrosine kinase inhibitor Staurosporine. Treatment with Staurosporine resulted in elongated neuronal processes imitating those present in vivo, compared with the control RGC-5 [13]. Our experiments further characterized this model, demonstrating differential expression of class III β-tublin, which highlighted the morphologic changes. This result thus provided an in vitro model that better approximates retinal ganglion cells in vivo.

Several mechanisms have been elaborated to explain the cytoprotective effect mediated by VEGF against oxidative stress [21,22]. In a study evaluating the role of growth factor-modulated antioxidant expression, Madhavan et al. [21] found elevated expression of the antioxidant enzyme superoxide dismutase 2 (SOD2). This enzyme protected neuronal cells from oxidative stress when exposed to 3-NP, an inhibitor of mitochondrial respiratory complex, in the presence of VEGF. Similarly, in animal models of hyperoxic acute lung injury, VEGF has been shown to protect vascular endothelial cells through induction of heme oxygenase-1 (HO-1) [22]. In this study, we demonstrated protection of differentiated retinal ganglion cells by hVEGF165 from oxidative stress induced by H2O2. Experiments using the glutathione reductase inhibitor BSO blunted this effect, indicating a potential role of glutathione in VEGF-mediated cytoprotection. An alternative explanation is that the oxidative stress was more robust in cells where endogenous reducing agents have been depleted, and any minimal cytoprotective action of VEGF was no longer evident.

Our conclusions are drawn from in vitro studies, which are at best approximate and cannot mimic in vivo conditions. Further, only one VEGF isoform was evaluated. Treatment with different isoforms may have highlighted differences between specific and non-specific VEGF inhibition. Lastly, the increased presence of class III β-tubulin provides evidence of neuronal elements, but this is not specific for retinal ganglion cells.

In summary, we offer in vitro evidence that VEGF protection against oxidative stress is blocked by bevacizumab, in a model of differentiated retinal ganglion cells.


1. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851–8. [PubMed]
2. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular Permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–12. [PubMed]
3. Wang Y, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA, Jin K. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci. 2007;27:304–7. [PMC free article] [PubMed]
4. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore PA. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol. 2003;264:275–88. [PubMed]
5. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47:3135–42. [PubMed]
6. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors. PLoS ONE. 2008;3:e3554. [PMC free article] [PubMed]
7. Kilic U, Kilic E, Järve A, Guo Z, Spudich A, Bieber K, Barzena U, Bassetti CL, Marti HH, Hermann DM. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci. 2006;26:12439–46. [PubMed]
8. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med. 2007;58:491–504. [PubMed]
9. Duh EJ, Yang HS, Haller JA, De Juan E, Humayun MS, Gehlbach P, Melia M, Pieramici D, Harlan JB, Campochiaro PA, Zack DJ. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol. 2004;137:668–74. [PubMed]
10. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7. [PubMed]
11. Gragoudas ES, Adamis AP, Cunningham ET, Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16. [PubMed]
12. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44. [PubMed]
13. Frassetto LJ, Schlieve CR, Lieven CJ, Utter AA, Jones MV, Agarwal N, Levin LA. Kinase-dependent differentiation of a retinal ganglion cell precursor. Invest Ophthalmol Vis Sci. 2006;47:427–38. [PubMed]
14. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115–34. [PubMed]
15. Jin GF, Hurst JS, Godley BF. Hydrogen peroxide stimulates apoptosis in cultured human retinal pigment epithelial cells. Curr Eye Res. 2001;22:165–73. [PubMed]
16. Rózanowska M, Jarvis-Evans J, Korytowski W, Boulton ME, Burke JM, Sarna T. Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. J Biol Chem. 1995;270:18825–30. [PubMed]
17. Izzotti A, Bagnis A, Saccà SC. The role of oxidative stress in glaucoma. Mutat Res. 2006;612:105–14. [PubMed]
18. Liu Q, Ju WK, Crowston JG, Xie F, Perry G, Smith MA, Lindsey JD, Weinreb RN. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage. Invest Ophthalmol Vis Sci. 2007;48:4580–9. [PubMed]
19. Tate DJ, Miceli MV, Newsome DA. Phagocytosis and H2O2 induce catalase and metallothionein gene expression in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1995;36:1271–9. [PubMed]
20. Castilla MA, Caramelo C, Gazapo RM, Martín O, González-Pacheco FR, Tejedor A, Bragado R, Arroyo MV. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci. 2000;67:1003–13. [PubMed]
21. Madhavan L, Ourednik V, Ourednik J. Neural stem/progenitor cells initiate the formation of cellular networks that provide neuroprotection by growth factor-modulated antioxidant expression. Stem Cells. 2008;26:254–65. [PubMed]
22. Siner JM, Jiang G, Cohen ZI, Shan P, Zhang X, Lee CG, Elias JA, Lee PJ. VEGF-induced heme oxygenase-1 confers cytoprotection from lethal hyperoxia in vivo. FASEB J. 2007;21:1422–32. [PubMed]

Articles from Molecular Vision are provided here courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China